# Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate

> **NCT00950989** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 252 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Brodalumab
- **DRUG:** Placebo
- **DRUG:** Methotrexate
- **DIETARY_SUPPLEMENT:** folic acid

## Key facts

- **NCT ID:** NCT00950989
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-30
- **Primary completion:** 2011-02-11
- **Final completion:** 2011-02-11
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2021-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00950989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00950989, "Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00950989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*